J. Van Loon
Mayo Clinic
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J. Van Loon.
Clinical Pharmacology & Therapeutics | 1984
Norman R.C. Campbell; Joel Dunnette; G. Mwaluko; J. Van Loon; Richard M. Weinshilboum
Methyldopa is metabolized by sulfate conjugation catalyzed by phenol sulfotransferase (PST), O‐methylation catalyzed by catechol‐O‐methyltransferase (COMT), and decarboxylation catalyzed by aromatic L‐amino acid decarboxylase. These experiments were performed to determine whether individual variations in red blood cell (RBC) COMT and platelet PST activities might reflect variations in the metabolism of methyldopa in man. Methyldopa, 3.5 mg/kg, was taken orally by 28 subjects. Blood samples were obtained from these subjects for the assay of platelet PST and RBC COMT activities, and a 24‐hr urine sample was collected for the measurement of methyldopa and its major metabolites. Human platelets contain two independently regulated forms of PST. One form is thermolabile (TL), and the other is thermostable (TS). Methyldopa and α‐methyldopamine are substrates for the TL but not for the TS form of PST. The results of the experiment showed significant correlations between TL platelet PST activity and the proportion of α‐methyldopamine excreted as a sulfate conjugate, and between RBC COMT activity and the proportion of methyldopa excreted as an O‐methyl metabolite. There was no significant correlation, however, between TL platelet PST activity, and the proportion of methyldopa itself excreted as a sulfate conjugate. These results are compatible with the conclusion that differences among subjects in drug metabolizing enzyme activities are one factor responsible for wide individual variations in methyldopa metabolism in man.
Xenobiotica | 1991
J. S. Hernández; J. Van Loon; Diane M. Otterness; R. Guerciolini; Richard M. Weinshilboum
1. Thiopurine methyltransferase (TPMT) catalyses the S-methylation of thiopurine drugs. TPMT activity in the kidneys of male Sprague-Dawley (S-D) rats is approximately twice that present in the kidneys of female S-D rats, and this difference is testosterone-dependent. Renal TPMT activities in these animals also increase dramatically during growth and development. 2. Our studies were conducted to determine whether variations in TMPT activity in the S-D rat kidney were due to differences in the quantity of TPMT protein. Rabbit polyclonal antibodies to partially purified rat kidney TPMT were used to develop an immunoprecipitation assay for immunoreactive TPMT protein. 3. Gender-related differences in renal TPMT activities in S-D rats were due to a lower content of immunoreactive TPMT protein in kidneys of female animals. TPMT enzyme activities and immunoreactive protein levels were also directly correlated in renal preparations from castrated and sham-operated male rats, from testosterone-treated castrated and sham-operated male rats, and from testosterone-treated and control female rats. 4. There was also a significant positive correlation between TPMT enzymic activities and immunoreactive TPMT protein levels in renal tissue from different aged male S-D rats (rs = 0.955, n = 15, P less than 0.001.) 5. These results demonstrate that changes in S-D kidney TPMT activity during growth and development, in the two sexes and in response to testosterone, were due to variations in the quantity of immunoreactive TPMT protein.
The Lancet | 1990
Lynne Lennard; J. S. Lilleyman; J. Van Loon; Richard M. Weinshilboum
Drug Metabolism and Disposition | 1989
Rajah S Sundaram; Carol L. Szumlanski; Diane M. Otterness; J. Van Loon; Richard M. Weinshilboum
Molecular Pharmacology | 1987
Norman R.C. Campbell; J. Van Loon; Rajah S Sundaram; C. Hansch; Richard M. Weinshilboum
Drug Metabolism and Disposition | 1990
J. Van Loon; Richard M. Weinshilboum
Journal of Pharmacology and Experimental Therapeutics | 1985
A L Kerremans; James J. Lipsky; J. Van Loon; M O Gallego; Richard M. Weinshilboum
Journal of Pharmacology and Experimental Therapeutics | 1987
J. Van Loon; Richard M. Weinshilboum
Journal of Pharmacology and Experimental Therapeutics | 1990
J. S. Hernández; J. Van Loon; Diane M. Otterness; Richard M. Weinshilboum
British Journal of Clinical Pharmacology | 1983
Christoph Reiter; Peter G. Werness; J. Van Loon; L H Smith; Richard M. Weinshilboum